Ravi Kant
Post-Doctoral Research Fellow University of Southampton, United Kingdom (UK) Email: R.kant@soton.ac.uk
VALIDATE Role: Network Associate
Research Keywords: Leishmaniasis, Vaccine Candidates, Reverse Vaccinology, Artificial Intelligence, Machine Learning
Biography: Dr. Ravi Kant is a Post-Doctoral Research Fellow at the Faculty of Medicine, University of Southampton, England, UK. As a Computational Biologist, his research focuses on identifying novel drug and vaccine candidates to address pressing global health challenges, particularly those caused by pathogens prioritized by the VALIDATE network, such as Leishmania. His expertise lies in leveraging advanced computational biology tools and artificial intelligence (AI) to design therapeutic interventions for neglected tropical diseases and sexually transmitted infections. Dr. Kant's primary research responsibilities encompass various aspects of the drug discovery and vaccine development pipeline, including homology modeling, pharmacophore generation, molecular docking, molecular dynamics simulations, and immunoinformatics. By integrating computational predictions with experimental validation, he aims to streamline the identification of immune-dominant epitopes and lead molecules for vaccine and therapeutic development against pathogens such as Leishmania and Mycobacterium tuberculosis. Throughout his nine-year research career, Dr. Kant has received numerous prestigious accolades, including the NIHR Southampton Biomedical Research Centre (BRC) Education, Training and Career Development Fund, the Bill & Melinda Gates Foundation Fellowship (eight times), the Young Investigator Award for India & Southeast Asia, the Young Scientist Award (three times), the Outstanding Research Scholar Award (twice), and most recently, the BBSRC-UKRI International Partnership Funding. Dr. Kant has been actively involved in international collaborations and knowledge exchange, traveling 14 times to countries such as the UK, United States, South Korea, Singapore, Canada, Thailand, South Africa, and Germany. He has presented his findings at global conferences and contributed to advancing research on vaccine candidates and therapeutics through publications and patents. His ongoing research projects, supported by major funding agencies like the Indian Council of Medical Research (ICMR), the Department of Biotechnology (DBT), Government of India, and BBSRC-UKRI in the UK, focus on computationally driven discovery of interventions for diseases caused by intracellular pathogens, including Leishmania. Dr. Kant’s work aligns closely with VALIDATE’s vision of fostering innovation, collaboration, and equity in addressing global health challenges, particularly in low- and middle-income countries.
Related Websites:
Key Publications:
|
